These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 29712435)

  • 21. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.
    Xu J; Ding X; Fu Y; Meng Q; Wang L; Zhang M; Xu C; Chen S; Aliper A; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 Jan; 67(2):1393-1405. PubMed ID: 38189253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
    Li L; Nakano D; Zhang A; Kittikulsuth W; Morisawa N; Ohsaki H; Suzuki N; Yamamoto M; Nishiyama A
    J Pharmacol Sci; 2020 Dec; 144(4):229-236. PubMed ID: 33070842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
    Yu Y; Yang F; Yu Q; Liu S; Wu C; Su K; Yang L; Bao X; Li Z; Li X; Zhang X
    J Med Chem; 2021 Dec; 64(23):17384-17402. PubMed ID: 34709043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
    Kato S; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
    Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G
    Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
    Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
    Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease.
    Mimura I; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2024 Jun; 25(9):1111-1120. PubMed ID: 38896547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats.
    Naito Y; Yasumura S; Okuno K; Asakura M; Tsujino T; Masuyama T; Ishihara M
    J Hypertens; 2024 Mar; 42(3):497-505. PubMed ID: 38014420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.
    Patel VJ; Joharapurkar A; Kshirsagar SG; Patel MS; Savsani HH; Dodiya HS; Rakhasiya MH; Kajavadara C; Valani D; Jain MR
    Toxicol Appl Pharmacol; 2024 Feb; 483():116832. PubMed ID: 38266872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enarodustat: First Approval.
    Markham A
    Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.